UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)

Annals of oncology, 2012-08, Vol.23 (8), p.1986-1992

2012

Volltextzugriff (PDF)

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Annals of oncology, 2014-07, Vol.25 (7), p.1328-1333

2014

Volltextzugriff (PDF)

Evaluation of Risk Factors Predicting Chemotherapy-Related Nausea and Vomiting: Results From a European Prospective Observational Study

Journal of pain and symptom management, 2014-05, Vol.47 (5), p.839-848.e4

2014

Volltextzugriff (PDF)

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy

Annals of oncology, 2014-07, Vol.25 (7), p.1333-1339

2014

Volltextzugriff (PDF)

Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis

Cancer research (Chicago, Ill.), 2010-11, Vol.70 (22), p.9003-9011

2010

Volltextzugriff (PDF)

The safety of intravenous fluorescein for confocal laser endomicroscopy in the gastrointestinal tract

Alimentary pharmacology & therapeutics, 2010-03, Vol.31 (5), p.548-552

2010

Volltextzugriff (PDF)

A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Clinical cancer research, 2014-04, Vol.20 (8), p.2192-2204

2014

Volltextzugriff (PDF)

Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

Clinical cancer research, 2013-05, Vol.19 (10), p.2766-2774

2013

Volltextzugriff (PDF)

Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma

Journal of clinical oncology, 2008-09, Vol.26 (27), p.4473-4479

2008

Volltextzugriff (PDF)

Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections

The New England journal of medicine, 2014-06, Vol.370 (23), p.2180-2190

2014

Volltextzugriff (PDF)

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

Clinical cancer research, 2012-08, Vol.18 (15), p.4173-4182

2012

Volltextzugriff (PDF)

Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas

European journal of cancer (1990), 2014-04, Vol.50 (6), p.1137-1147

2014

Volltextzugriff (PDF)

Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes

JNCI : Journal of the National Cancer Institute, 2009-12, Vol.101 (23), p.1624-1632

2009

Volltextzugriff (PDF)

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

The Lancet infectious diseases, 2013-05, Vol.13 (5), p.401-408

2013

Volltextzugriff (PDF)

The Economic Burden of Toxicities Associated with Cancer Treatment: Review of the Literature and Analysis of Nausea and Vomiting, Diarrhoea, Oral Mucositis and Fatigue

PharmacoEconomics, 2013-09, Vol.31 (9), p.753-766

2013

Volltextzugriff (PDF)

Management of Chemotherapy-Induced Nausea and Vomiting: Focus on Newer Agents and New Uses for Older Agents

Drugs (New York, N.Y.), 2013-03, Vol.73 (3), p.249-262

Navari, Rudolph M.

2013

Volltextzugriff (PDF)

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

European journal of cancer (1990), 2013-09, Vol.49 (14), p.2972-2978

2013

Volltextzugriff (PDF)

Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

Annals of oncology, 2013-04, Vol.24 (4), p.1067-1073

2013

Volltextzugriff (PDF)

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

Investigational new drugs, 2014-06, Vol.32 (3), p.436-444

2014

Volltextzugriff (PDF)

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

Clinical cancer research, 2012-09, Vol.18 (17), p.4775-4784

2012

Volltextzugriff (PDF)

U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive

Clinical cancer research, 2014-04, Vol.20 (8), p.2029-2034

2014

Volltextzugriff (PDF)

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

European journal of cancer (1990), 2013-08, Vol.49 (12), p.2633-2642

2013

Volltextzugriff (PDF)

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer

European journal of cancer (1990), 2013-12, Vol.49 (18), p.3763-3772

2013

Volltextzugriff (PDF)

First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors

Clinical cancer research, 2014-04, Vol.20 (8), p.2205-2214

2014

Volltextzugriff (PDF)

1 – 25 von 1.857

Suche als RSS-Feed

Aktive Filter

ThemaPharmacology. Drug Treatments

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.712)
Mit Volltextzugriff
(1.385)

Publikationsform

Artikel
(1.857)

Sprache

Englisch
(1.857)

Erscheinungsjahr

n.n

Thema

Biological And Medical Sciences
(1.857)
Medical Sciences
(1.857)
Humans
(1.823)
Life Sciences & Biomedicine
(1.703)
Science & Technology
(1.703)
Nausea - Chemically Induced
(1.672)
Female
(1.436)
Adult
(1.243)
Male
(1.224)
Middle Aged
(1.208)
Vomiting - Chemically Induced
(934)
Aged
(930)
Oncology
(786)
Antineoplastic Agents
(624)
Chemotherapy
(581)
Pharmacology & Pharmacy
(434)
Treatment Outcome
(424)
Drug Toxicity And Drugs Side Effects Treatment
(423)
Antineoplastic Agents - Adverse Effects
(402)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Evaluation of Risk Factors Predicting Chemotherapy-Related Nausea and Vomiting: Results From a European Prospective Observational Study

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy

Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis

The safety of intravenous fluorescein for confocal laser endomicroscopy in the gastrointestinal tract

A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma

Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas

Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

The Economic Burden of Toxicities Associated with Cancer Treatment: Review of the Literature and Analysis of Nausea and Vomiting, Diarrhoea, Oral Mucositis and Fatigue

Management of Chemotherapy-Induced Nausea and Vomiting: Focus on Newer Agents and New Uses for Older Agents

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive

Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer

First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors

Aktive Filter

Suchergebnisse filtern